BioScreening - organic compounds for screening

30.07.2004 July 2004 News Archive
Dyax Corp has granted a non-exclusive license to its proprietary antibody phage display libraries to Amgen for the discovery of human antibodies for therapeutic and diagnostic product development. Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, product license exercise fees, clinical milestone payments, and royalties on net sales of products that may result from Amgen's use of the Dyax libraries. The agreement provides Amgen with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology. PR-Dyax 7/30/04

Anadys Pharmaceuticals announced it has entered into a new drug discovery collaboration with Roche. The two companies began a partnership in August 2002 that utilized Anadys'  drug discovery capabilities to advance lead compounds against a Roche oncology program. This agreement was expanded in October 2003. Under the new agreement, Anadys will engage its drug discovery capabilities, including medicinal chemistry, structure-based drug design, cheminformatics and biology to advance lead compounds against an additional undisclosed Roche program. PR-AP 7/29/04

Sunesis Pharmaceuticals and Merck announced that they have entered into a multi-year research collaboration to discover novel oral drugs for the treatment of viral infections. Sunesis will provide Merck with a series of small molecule compounds targeting viral infections. These compounds were derived from Tethering, Sunesis' proprietary fragment-based drug discovery platform. PR-MRK  7/27/04

Locus Pharmaceuticals and Procter & Gamble Pharmaceuticals, Inc. (P&GP), have reached agreement on a research collaboration to design new drugs for the treatment of diabetes. The drug target chosen by P&GP represents a new approach for the treatment of diabetes, a disease that is a growing problem worldwide. Locus will apply its computational drug design technology to identify new binding sites on the target protein. PR-LP 7/26/04

AnalytiCon Discovery and the Experimental Therapeutics Center at Memorial Sloan-Kettering Cancer Center have entered into a multi year drug discovery, pre-clinical and clinical research collaboration to identify novel drug candidates in the area of oncology. The collaboration will bring together AnalytiCon's collection of pure natural products with elucidated structures, natural product and medicinal chemistry expertise with MSKCC's cancer cell systems and biology, high-throughput screening technologies and clinical research expertise. PR-AD 7/23/04

Peakdale Molecular announces the expansion of its Peakexplorer™ screening libraries, with the launch of a second G-Protein Coupled Receptor focused collection. The G2 library, which has been launched six weeks earlier than scheduled, combines the Company's proprietary chemistry with De Novo Pharmaceuticals in silico design. PR-Peak 7/21/04 

Locus Pharmaceuticals acquires Protein Mechanics, a four-year old drug discovery company which developed ground-breaking simulation technology for the design of small molecule therapeutics. This novel and proprietary computational technology evolved from nearly 20 years of cross-disciplinary simulation research of complex, dynamic mechanical systems in the engineering industry. Protein Mechanics was founded on the principle of applying this in silico engineering approach to the simulation of protein movement, which results in highly accurate protein structures that are critical to the success of de novo drug design. PR-LR 7/20/04

IBM scientists have achieved a breakthrough in nanoscale magnetic resonance imaging (MRI) by directly detecting the faint magnetic signal from a single electron buried inside a solid sample. This achievement is a major milestone toward creating a microscope that can make 3-D images of molecules with atomic resolution. Success in this quest should have major impact on the study of materials -- ranging from proteins and pharmaceuticals to integrated circuits and industrial catalysts -- for which a detailed understanding of the atomic structure is essential. PR-IBM 7/14/07

Olympus has launchesd a laser scanning confocal microscope, the FluoView™ FV1000, for high-resolution confocal imaging of living cells. The FV1000 offers a scanning system with two independent, fully synchronized laser scanners for simultaneous confocal high resolution imaging and laser stimulation. This microscope boasts improved fluorescence imaging of living cells. PR-Olympus 7/13/04

General Electric  through GE Global Research, along with Celera Genomics Group, an Applera Corporation business, and Celera Diagnostics, a joint venture between Celera Genomics and the Applied Biosystems Group of Applera, announced a joint research collaboration intended to accelerate the discovery and development of new products for personalized, or targeted, medicine. The parties will seek to understand and differentiate disease at the molecular level, which is expected to lead to new diagnostics and treatments that are tailored for a specific disease and/or patient population. PR-GE 7/12/04

Jubilant Biosys, an innovative bioinformatics and chemoinformatics service provider have licensed their database of small molecules that focuses on Kinase targets, the Kinase ChemBioBase™ and PathArt™- the world’s largest database of Manually Curated Pathways to the National Cancer Institute. The Kinase ChemBioBase™ contains over 190,000 molecules covering over 300 kinase targets, and has around 210,000 quality-checked SAR points comprising of IC50, EC50, percentage inhibition, ED50, LD50, Ki, Km etc.PathArt™ has over 900 signaling and metabolic pathways manually curated from full text literature. PR-Jubilant 7/9/04.

Atugen AG has signed a contract research agreement with Eisai London Research Laboratories (ELL), a subsidiary of Eisai Co., Ltd., Japans fourth largest pharmaceutical company. This is the first agreement between the two companies. The contract covers target validation and lead optimization and atugen will use its gene silencing technologies, including siRNA, GeneBlocs®, delivery reagents and cell line optimization for an undisclosed number of Eisai targets. PR 7/6/04

Peakdale Molecular and De Novo Pharmaceuticals have entered into a joint collaboration to exploit their respective skills in chemistry synthesis and molecular design. De Novo has world-leading proprietary expertise for the in silico de novo design of novel chemotypes against biological enzyme and receptor targets. De Novo’s proprietary technology Quasi2™ allows the generation of feature rich, “extended pharmacophore” models from known active ligands allowing drug design in the absence of structural data. Using its validated de novo structure generation technology, SkelGen II™, De Novo is able to effectively sample the diversity of chemical space providing novel chemotype designs to address a given target. PR-Peakdale 7/5/04

BD (Becton, Dickinson and Company) through its BD Biosciences segment announced it has acquired Atto Bioscience in a cash transaction valued at approximately $25 million. Atto Bioscience, a privately held MD-based company, specializes in optical instrumentation, software, and reagents for real-time analysis of interactions taking place in living cells. PR-BD 7/1/04

Compugen Ltd. has establishment of a new subsidiary, Keddem Bioscience Ltd., focused on small molecule drug discovery. The program now being transferred to the new company was initiated in 2000 as the chemistry division of Compugen.  The subsidiary's offices and laboratories are located in Ashkelon, Israel. PR-Compugen 7/1/04
More bioscreening news...

new | june 2010 | october 2009 | may 2009 | january 2009 | october 2008 | april 2008 | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003